Skip to main content
SpringerLink
Log in

Cephalosporins and Cephamycins

  • Chapter
Antibiotics in Obstetrics and Gynecology

Part of the book series: Developments in Perinatal Medicine ((DIPM,volume 2))

  • 99 Accesses

Abstract

The clinician is faced with a veritable explosion in the investigation and introduction of cephalosporin and cephalosporinlike antibiotics. Although very little clinical and in vitro differences exist between the first generation cephalosporins (Fig. 1), there has been a steady proliferation of these agents. Although, the clinical efficacy of this versatile group of first generation cephalosporins, which are broad spectrum bactericidal beta lactam antibiotics, is well established, in fact, they are not the drug of choice for any specific infection. However, they have become the second choice drugs for many bacterial infections. This confusing situation will become even more complex, as the so-called second and third generation cephalosporins receive either widespread use or introduction into clinical medicine. This second generation and third generation of cephalosporins have enhanced broad spectrum antimicrobial activity, which may be of clinical importance. The cephamycin group of antibiotics which are related to he cephalosporins also have come into being.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abraham EP, Loder PB: Cephalosporin C. In: Flyn EH (ed). Cephalosporins and penicillins. New York: Academic Press, 1972

    Google Scholar 

  2. Moellering RC: Cefamandole–a new member of the cephalosporin family. J Infect Dis 137: 52–59, 1978

    Google Scholar 

  3. Moellering RC, Swartz MN: The newer cephalosporins. N Engl J Med 294: 24–28, 1976

    PubMed  CAS  Google Scholar 

  4. Silverblatt F, Harrison WO, Turck M: Nephrotoxicity of cephalosporin antibiotics in experimental animals. J Infect Dis 128 (Suppl): S367 - S372, 1973

    PubMed  Google Scholar 

  5. Maudell G: Cephaloridine. Ann Intern Med 79: 561–565, 1973

    Google Scholar 

  6. Foord RD: Cephaloridine, cephaloth, and the kidney. J Antimicrob Chemother 1 (Suppl): 119–133, 1975

    PubMed  CAS  Google Scholar 

  7. Barza M: The nephrotoxicity of cephalosporins: An overview. J Infect Dis 137: 560–573, 1978

    Google Scholar 

  8. Andriole VT: Pharmacokinetics of cephalosporins in patients with normal or reduced renal function. J Infect Dis 137: 588–597, 1978

    Google Scholar 

  9. Richmond, MH, Wottin S: Comparative study of seven cephalosporins: susceptibility to B-lactamases and ability to penetrate the surface layers of Escherichia coll. Antimicrob Agents Chemother 10: 219–222, 1976

    PubMed  CAS  Google Scholar 

  10. Farrar WE, Jr, O’Dell NM: Beta-lactamases and resistance to penicillins and cephalosporins in Serratia marcescens. J Infect Dis 134: 245–251, 1976

    PubMed  CAS  Google Scholar 

  11. Nagarajan R, Boech LD, Gordon M, et al.: Beta-lactam antibiotics from streptomyces. J Am Chem Soc 93: 2308–2310, 1971

    PubMed  CAS  Google Scholar 

  12. Stapley EP, Jackson M, Hernanez S, et al.: Cephamycins, a new family of B-lactam antibiotics. I. Production by actinomycetes, including Streptonyces lactamdurans sp.n. Antimicrob Agents Chemother 2: 122–31, 1979

    Google Scholar 

  13. Kass EH, Evans DA: Introduction. Rev Infect Dis 1: 2–4, 1979

    Google Scholar 

  14. Wick WE, Preston D: Biological properties of three 3-heterocyclic-thiomethyl cephalosporin antibiotics. Antimicrob Agents Chemother 1: 221–234, 1972

    PubMed  CAS  Google Scholar 

  15. Webber JA, Ott JL: Structure-activity relationships in the cephalosporins. II. Recent developments. In: D. Perlman (ed). Structure/activity relationships among the semi-synthetic antibiotics. New York: Academic Press, 1977, pp. 161–237

    Google Scholar 

  16. Meyers B, Leng B, Hirschman S: Cefamandole: antimicrobial activity in vitro of a new cephalosporin. Antimicrob Agents Chemother 8: 737–741, 1975

    PubMed  CAS  Google Scholar 

  17. Bodey GP, Weaver S: In vitro studies of cefamandole. Antimicrob Agents Chemother 9: 452–457, 1976.

    PubMed  CAS  Google Scholar 

  18. Washington JA, II: The in vitro spectrum of the cephalosporins. Mayo Clin Proc 51: 237–250, 1976

    PubMed  CAS  Google Scholar 

  19. Griffith RS, Black HR, Brier GL, Wolney JD: Cefamandole: in vitro and clinical pharmacokinetics. Antimicrob Agents Chemother 10: 814–823, 1976

    PubMed  CAS  Google Scholar 

  20. Neu HC: Cefamandole: a cephalosporin antibiotic with an unusually wide spectrum of activity. Antimicrob Agents Chemother. 6: 177–182, 1974

    PubMed  CAS  Google Scholar 

  21. Shemonsky NK, Carrizosa J, Levison ME: In vitro activity and pharmacokinetics in patients of cefamandole, a new cephalosporin antibiotic. Antimicrob Agents Chemother 8: 679–683, 1975

    PubMed  CAS  Google Scholar 

  22. Eykyn S, Jenkins C, King A, Phillips I: Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin. Antimicrob Agents Cehmother 6: 657–661, 1973

    Google Scholar 

  23. Jones RN, Fuchs PC: Comparison of in vitro antimicrobial activity of cefamandole and cefazolin with cephalothin against over 8,000 clinical bacterial isolates. Antimicrob Agents Chemother 9: 1066–1069, 1976

    PubMed  CAS  Google Scholar 

  24. Knothe H, Laver B: The microbiOlogical comparison of cephalothin, cephalexin, cephacetrile, cephradine, cefazolin, and cefamandole. Adv Clin Pharmcol 8: 80–88, 1974

    CAS  Google Scholar 

  25. Washington JA, II: Differences between cephalothin and newer parenterally absorbed cephalosporins in vitro: a justification for separate discs. J Infect Dis 137 (Suppl): S32 - S37, 1978

    PubMed  Google Scholar 

  26. Meyers BR, Hirschman SZ: Antibacterial activity of cefamandole in vitro. J Infect Dis 137 (Suppl): S25 — S31, 1978

    PubMed  Google Scholar 

  27. Kaiser GV, Gorman M, Webber JA: Cefamandole — A review of chemistry and microbiology. J Infect Dis 137 (Suppl): S10 — S16, 1978

    PubMed  Google Scholar 

  28. Fu KP, Neu HC: A comparative study of the activity of cefamandole and other cephalosporins and analysis of the B-lactamase stability and synergy of cefamandole with amino-glycosides. J. Infect Dis (Suppl) 137: S38 — S48, 1978

    Google Scholar 

  29. Weinrich AE, Del Bene VE: Beta-lactamase activity in anaerobic bacteria. Antimicrob Agents Chemother 10: 106–11, 1976

    PubMed  CAS  Google Scholar 

  30. Sutter VL, Finegold SM: Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob Agents Chemother 10: 736–52, 1976

    PubMed  CAS  Google Scholar 

  31. Ernst EC, Berger S, Barza M, Jacobus NV, Tally FP: Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 9: 852–855, 1976.

    PubMed  CAS  Google Scholar 

  32. Darland G, Birnbaum J: Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of Bacteroides fragilis to the antibiotic. Antimicrob Agents Chemother 11: 725–734, 1977

    PubMed  CAS  Google Scholar 

  33. Eykyn S, Jenkins C, King A, Phillips I: Antibacterial activity of cefuroxime, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin and cefamandole. Antimicrob Agents Chemother 9: 690–695, 1976

    PubMed  CAS  Google Scholar 

  34. Chow AW, Bednorz D: Comparative in vitro activity of newer cephalosporins against anaerobic bacteria. Antimicrob Agents Chemother 14: 668–671, 1978

    PubMed  CAS  Google Scholar 

  35. Wold JS, Joost RR, Black HR, Griffith RS: Hydrolysis of cefmandole nafate to cefamandole in vivo. J Infect Dis 137 (Suppl): 517–524, 1978

    Google Scholar 

  36. Turner JR, Preston DA, Wold JS: Delineation of the relative antibacterial activity of cefamandOle and cefamandole nafate. Antimicrob Agents Chemother 11: 105–109, 1977

    Google Scholar 

  37. Fong IW, Ralph ED, Engelking ER, Kirby WMM: Clinical pharmacology of cefamandole as compared with cephalothin. Antimicrob Agents Chemother 9: 65–69, 1976

    PubMed  CAS  Google Scholar 

  38. Meyers BR, Ribner B, Yancovitz S, Hirschman SZ: Pharmacological studies with cefamandole in human volunteers. Antimicrob Agents Chemother 9: 140–144, 1973

    Google Scholar 

  39. Russell DG, Levine LR, McCain E: Cefamandole in the treatment of anaerobic infections. 17th Interscience Conference on Antimicrobial Agents anD Chemotherapy, New York, 12–14 October, 1977 (Abstract No. 1974 )

    Google Scholar 

  40. Greenberg RN, Scalcine MC, Sanders CV, Lewis AC: Cefamandole therapy for anaerobic infections. Antimicrob Agents Chemother 15: 337–341, 1979

    PubMed  CAS  Google Scholar 

  41. Perkins RL, Fass RJ, Warner JF, et al.: Cefamandole nafate therapy of respiratory tract, skin and soft tissue infection in 74 patients. J Infect Dis 137 (Suppl): S110 — S118, 1978

    PubMed  Google Scholar 

  42. Plaut ME, Perlino CA: Cefamandole vs. Procaine Penicillin for treatment of pneumonia due to Streptococcus pneumoniae. J Infect Dis 137 (Suppl) S133 — S138, 1978

    PubMed  Google Scholar 

  43. Gentry LO: Efficacy and safety of cefamandole plus either gentamicin or tobramycin in therapy of severe Gram-negative bacterial infections. J Infect Dis 137 (Suppl): S144 — W149, 1978

    PubMed  Google Scholar 

  44. Stone HH, Guest BS, Geheb CE, et al.: Cefamandole in treatment of peritonitis. J Infect Dis 137 (Suppl): S103–5109, 1978

    PubMed  Google Scholar 

  45. Levine LR: Cefamandole in the treatment of anaerobic infections. Contemp Surg 13: 33–37, 1978

    Google Scholar 

  46. Cunningham FG, Gilstrap LC: Treatment of obstetrics and gynecologic infections with cefamandole. Am J Obstet Gynecol 133: 602–610, 1979

    PubMed  CAS  Google Scholar 

  47. Gibbs RS, Huff RW: Therapy of puerperal endomyometritis with intravenous cefamandole. Am J Obstet Gynecol 136: 32–37, 1980

    PubMed  CAS  Google Scholar 

  48. Leveine LR, MCCain, E: Clinical experieNce with cefamandole for treatment of serious bone and joint infections. J Infect Dis 137 (Suppl): S117–5124, 1978

    Google Scholar 

  49. Slama TG, Fass RJ: Comparative efficacy of prophylactic cephalothin and cefamandole for elective colon surgery. 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, 1–4 October, 1978. (Abstract 10)

    Google Scholar 

  50. Bartlett JG, Louie TJ, Gorbach SL, et al.: Comparative efficacy of three cephalosporins and cefoxitin in experimental intra-abdominal sepsis. Current Chemotherapy: Proc. 10th International Congress Chemotherapy. Siegenthaler W, Luthy R (eds.) Washington, D.C.: American Society Microbiology, 1978, pp. 298–299

    Google Scholar 

  51. Kreutner AK, Del Bene VE, Delamar D, et al.: Perioperative cephalosporin prophylaxis in cesarean section: effect on endometritis in the high-risk patient. Am J Obstet Gynecol 134: 925–933, 1979

    PubMed  CAS  Google Scholar 

  52. Long WH, Rudd EG, Dillon MB.: Intrauterine irrigation with cefamandole nafate solution at cesarean section: a preliminary report. Am J Obstet Gynecol 138: 755–758, 1980

    PubMed  CAS  Google Scholar 

  53. Miller AK, Celozzi E, Pelak BA, et al.: Cephamycin, a new family of Beta-lactam antibiotics. III. In vitro studies. Antimicrob Agents Chemother 2:281–286, 1972

    Google Scholar 

  54. Onishi HR, Daouse DR, Zimmerman SB, et al.: Cefoxitin, a semisynthethic cephamy n antibiotic: Resistance to Beta-lactamase inactivation. Antimicrob Agents Chemother 5: 38–48, 1974

    PubMed  CAS  Google Scholar 

  55. Stapley EO, Birnbaum J, Miller AK, et al.: Cefoxitin and cephamycins: Microbiological studies. Rev Infect Dis 1: 73–89, 1979

    PubMed  CAS  Google Scholar 

  56. Karady S, Pines SH, Weinstock LM, et al.: Semisynthetic cephalosporins via a novel acyl exchange reaction. J Am Chem Soc 94: 1410–1411, 1972

    PubMed  CAS  Google Scholar 

  57. Wallick H, Hendlen D: Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies. Antimicrob Agents Chemother 5: 25–32, 1974

    PubMed  CAS  Google Scholar 

  58. Jones RN, Thornesberry C, Barny AL, et al.: BL-5786, a new parenteral cephalosporin II. In vitro antimicrobial activity in comparison with six related cephalosporins. J Antibiot (Tokyo) 30:583–587, 1977

    Google Scholar 

  59. Phillips I, King A, Warren C, et al.: The activity of penicillin and eight cephalosporins on N. gonorrhoeae. J Antimicrob Chemother 2: 31–39, 1976

    PubMed  CAS  Google Scholar 

  60. Sutter VL, Kriby B, Finegold SM: In vitro activity of cefoxitin and parenterally administered cephalosporins against anaerobic bacteria. Rev Infect Dis 1: 218–222, 1979

    PubMed  CAS  Google Scholar 

  61. Neu HC: Cefoxitin, a semisynthetic cephamycin antibiotic: Antibacterial spectrum and resistance to hydrolysis by Gram-negative beta-lactamases. Antimicrob Agents Chemother 6: 170–176, 1974

    PubMed  CAS  Google Scholar 

  62. Moellering RC, Jr, Dray M, Kunz LJ: Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin. Antimicrob Agents Chemother 6: 320–323, 1974

    PubMed  CAS  Google Scholar 

  63. Tall FP, Jacobus NV, Bartlett JG, Borbach SL: Susceptibility of anaerobes to cefoxitin and oTher cephalosporins. Antimicrob Agents Chemother 7: 128–132, 1975

    Google Scholar 

  64. Sutter VL, Finegold SM: Susceptibility of anaerobic bacteria to carbenicillin, cefoxitin, and related drugs. J Infect Dis 131: 417–422, 1975

    PubMed  CAS  Google Scholar 

  65. Darland G, Birnbaum J: Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of Bacteroides to the antibiotic. Antimicrob Agents Chemother 11: 725–734, 1977

    PubMed  CAS  Google Scholar 

  66. Berg SW, Kilpatrick ME, Harrison WO, McCutchan JA: Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 301: 509–511, 1979

    PubMed  CAS  Google Scholar 

  67. Humbert G, Fillaster JP, Leroy A, et al.: Pharmacokinetics of cEfoxitin in normal subjects and in patients with renal insufficiency. Rev Infect Dis 1: 118–126, 1979

    PubMed  CAS  Google Scholar 

  68. Schrogie JJ, Rogers JD, Yeh HC, et al.: Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. Rev Infect Dis 1: 90–98, 1979

    PubMed  CAS  Google Scholar 

  69. Adams HG, Stilwell GA, Turck M: In vitro evaluation of cefoxitin and cefamandole. Antimicrob Agents Chemother 9: 1019–1024, 1976

    PubMed  CAS  Google Scholar 

  70. Eickhoff TC, Ehret JM: In vitro comparison of cefoxitin, cefamandole, cephalexin, and cephalothin. Antimicrob Agents Chemother 9: 994–999, 1976

    PubMed  CAS  Google Scholar 

  71. George WL, Lewis RP, Meyer RD: Susceptibility of cephalothin-resistant Gram-negative bacilli to piperacillin, cefuroxime, and other selected antibiotics. Antimicrob Agents Chemother 13: 484–489, 1978

    PubMed  CAS  Google Scholar 

  72. Lewis RP, Meyer RD, Kraus LL: Antibacterial activity of selected beta-lactam and aminoglycoside antibiotics against cephalothin-resistant Enterobacteriaciae. Antimicrob Agents Chemother 9: 780–786, 1976

    PubMed  CAS  Google Scholar 

  73. Busch DF, Hesitine PNR, Meyer RD, et al.: Cefoxitin sodium therapy of anaerobic infections. J Antimicrob Chemother 4 (Suppl. B): 197–202, 1978

    PubMed  CAS  Google Scholar 

  74. Gorbach SL, Miao PVW, O’Keefe JP, Tally FP: Treatment of anaerobic infections with cefoxitin. In: Current chemotherapy. W. Siegenthaler and R. Luthy (eds). Washington, D.C.: American Society Microbiology, 1978, pp. 300–302.

    Google Scholar 

  75. Heseltine PNR, Busch DF, Meyer RD, Finegold SM: Cefoxitin: clinical evaluation in thirty-eight patients. Antimicrob Agents Chemother 11: 427–434, 1977

    PubMed  CAS  Google Scholar 

  76. McCloskey RV: Cefoxitin sodium treatment of anaerobic and polymicrobial aerobic infections. J Antimicrob Chemother 4 (Suppl. B): 223–225, 1978

    PubMed  CAS  Google Scholar 

  77. Weinstein MP, Eickhoff TC: Clinical evaluation of cefoxitin in the treatment of respiratory tract and other acute bacterial infections. Rev Infect Dis 1: 158–164, 1979

    PubMed  CAS  Google Scholar 

  78. Perkins RL, Slama TG, Fass RJ, et al.: Therapy of skin, soft tissue, and bone infections with cefoxitin sodium. Rev Infect Dis 1: 165–169, 1979

    PubMed  CAS  Google Scholar 

  79. Alford RH: Infections Due to endemic, multiple resistant Gram-negative rods: sensitivity to and therapy with cefoxitin. Rev Infect Dis 1: 175–182, 1979

    PubMed  CAS  Google Scholar 

  80. Pazin, GJ, Schwartz SN, Ho M, et al.: Treatment of septicemic patients with cefoxitin: pharmacokinetics in renal insufficiency. Rev Infect Dis 1: 189–194, 1979

    PubMed  CAS  Google Scholar 

  81. Rambo WM, Del Bene VE, Delamar DK: Cefoxitin therapy for surgical patients. Rev Infect Dis 1: 195–198, 1979

    PubMed  CAS  Google Scholar 

  82. Laplante L, Bastienn E, Giroux Y, Girard R: Intravenous treatment of systemic infections in 20 patients with cefoxitin sodium. J Antimicrob Chemother 4 (Suppl.B): 219–222, 1978

    PubMed  CAS  Google Scholar 

  83. Nair SR, Cherubin CE: Use of cefoxitin, new cephalosporinlike antibiotic in the treatment of aerobic and anaerobic infections. Antimicrob Agents Chemother 14: 866–75, 1978

    PubMed  CAS  Google Scholar 

  84. Schumer W, Nichols RL, Acharya A: Use of cefoxitin sodium in moderate to severe surgical infections. J Antimicrob Chemother 4 (Suppl B): 231–233, 1978

    PubMed  CAS  Google Scholar 

  85. Wilson P, Leung T, Williams JD: Antibacterial activity, pharmacokinetics and efficacy of cefoxitin in patients with abdominal sepsis and other infections. J Antimicrob Chemother 4 (Suppl. B): 127–141, 1978

    PubMed  CAS  Google Scholar 

  86. Gonzalez-Enders, R, Calderon J, Trelles J: Treatment of postpartum endometritis with cefoxitin. In: Current chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, 1977. 11:768–770, 1977

    Google Scholar 

  87. Ledger WJ, Smith D: Cefoxitin in obstetric and gynecologic infection. Rev Infect Dis 1: 199–201, 1979

    PubMed  CAS  Google Scholar 

  88. Sweet RL, Hadley HW Mills J, et al.: Cefoxitin in the treatment of pelvic infections. In: Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, 1977. 11:767–768, 1977

    Google Scholar 

  89. Sweet RL, Ledger WJ: Cefoxitin: Simple-agent treatment of mixed aerobic-anaerobic pelvic infections. Obstet Gynecol 54: 193–198, 1979

    PubMed  CAS  Google Scholar 

  90. Mickal A, Curole D, Lewis C: Cefoxitin sodium: doubleblind vaginal hysterectomy prophylaxis in premenopausal patients. Obstet Gynecol 56: 222–225, 1980

    PubMed  CAS  Google Scholar 

  91. Hemsell DL, Cunningham FG, Kappus S, Nobles B: Cefoxitin for prophylaxis in premenopausal women undergoing vaginal hysterectomy. Obstet Gynecol 56: 629–634, 1980

    PubMed  CAS  Google Scholar 

  92. Harding GKM, Yuen CK, Thompson MJ, Lank B: A prospective randomized comparison of cefoxitin, cefazolin, and placebo in premenopausal women undergoing vaginal hysterectomy. 20th Interscience Conference Antimicrobial Agents Chemotherapy, New Orleans, La., September 2–24, 1980. Abstract #228.

    Google Scholar 

  93. Ledger WJ: Personal communication.

    Google Scholar 

  94. Harger J, English D: Perioperative cefoxitin prophylaxis in Cesarean section at high risk for infection. 20th Interscience Conference Antimicrobial Agents Chemotherapy, New Orleans, La., September 22–24, 1980. Abstract # 229

    Google Scholar 

  95. Polk F: Personal communication.

    Google Scholar 

  96. Jones RN, Fuchs PC, Barry AL, et al.: Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates. Clin Therapeutics, 3 (Suppl): 14–23, 1980

    CAS  Google Scholar 

  97. Hinkle AM, LeBlanc BM, Bodey GP: In vitro evaluation of cefoperazone. Antimicrob Agents Chemother 17: 423–427, 1980

    PubMed  CAS  Google Scholar 

  98. Kurtz TO, Winston DJ, Hundler JA, et al.: Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against Gram-negative bacilli. Antimicrob Agents Chemother 18: 645–648, 1980

    PubMed  CAS  Google Scholar 

  99. Kaye D, Kobasa W, Kaye K: Susceptibility of anaerobic bacteria to cefoperazone and other antibiotics. Antimicrob Agents Chemother 17: 957–960, 1980

    PubMed  CAS  Google Scholar 

  100. Matsubara N, Minami S, Muraoka T, et al.: In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin. Antimicrob Agents Chemother 16: 731–735, 1979

    PubMed  CAS  Google Scholar 

  101. Neu HC, Fu KP, Aswapokee AN, et al.: Comparative activity and B-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother 16: 150–157, 1979

    PubMed  CAS  Google Scholar 

  102. Hall WH, Opfer BJ, Gerding DN: Comparative activities of the oxa-B-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant Gram-negative bacilli. Antimicrob Agents Chemother. 12: 273–279, 1980

    Google Scholar 

  103. Ledger WJ: Cefoperazone in the treatment of patients withgynecological infections. Cefoperazone Symposium. New Orleans, 1980, Excerpta Medica.

    Google Scholar 

  104. Neu HC, Aswapokee N, Aswapokee P, Fu KP: HR756, a new cephalosporin active against Gram-positive and Gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother 15: 273–281, 1979

    PubMed  CAS  Google Scholar 

  105. Greenwood D, Pearson N, Eley A, O’Grady F: Comparative in vitro activities of cefoTaxime and ceftizoxime (FK749): new cephalosporins with exceptional potency. Antimicrob Agents Chemother 17: 397–401, 1980

    PubMed  CAS  Google Scholar 

  106. Drasar FA, Farrell W, Howard M, et al.: Activity of HR756 against Haemophilus influenzae. Bacteroides fragilis, and Gram-negative rods. J Antimicrob Chemother 4: 445–450, 1978

    PubMed  CAS  Google Scholar 

  107. Hamilton-Miller JMT, Brumfitt W, Reynolds AV: Cefotaxime (HR756) a new cephalosporin with exceptional bropd-spectrum activity in vitro J Antimicrob Chemother 4: 437–444, 1978

    CAS  Google Scholar 

  108. Sosna JP, Murray PR, Medoff G: Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin and cefamandole. Antimicrob Agents Chemother 14: 876–879, 1978

    PubMed  CAS  Google Scholar 

  109. Murray PR, Christman JL, Medoff G: In vitro activity of HR756, a new cephalosporin, against Neisseria gonorrhoeae. Antimicrob Agents Chemother 15: 452–454, 1979

    PubMed  CAS  Google Scholar 

  110. Hemsell DL, Cunningham FG, DePalma SS, et al.: Treatment of obstetric and gynecologic infections with cefotaxime. 20th Interscience Conference of Antimicrobial Agents and Chemotherapy. Abstract No. 19, New Orleans, La., September 22–24, 1980

    Google Scholar 

  111. Yoshida T, Matsuura S, Mayama M, Kameda Y, Kuwahara S: Moxalactam (6059-S), a novel 1-oxa-ß-lactam with an expander antibacterial spectrum: laboratory evaluation. Antimicrob Agents Chemother 17: 302–312, 1980

    PubMed  CAS  Google Scholar 

  112. Jorgensen JH, Crawford SA, Alexander GA: In vitro activities of moxalactam and cefotaxime against aerobic Gram-negative bacilli. Antimicrob Agents Chemother 17: 937–942, 1980

    PubMed  CAS  Google Scholar 

  113. Fass RJ: In vitro activity of LY127935. Antimicrob Agents Chemother 16: 503–509, 1979

    PubMed  CAS  Google Scholar 

  114. Reimer LG, Mirrett S, Reller LB: Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates. Antimicrob Agents Chemother 17: 412–416, 1980

    PubMed  CAS  Google Scholar 

  115. Gibbs RS, Blanco JD, Castaneda YS, St.Clair PJ: Therapy of obstetrical infections with moxalactaM. Antimicrob Agents Chemother 17: 1004–1007, 1980

    PubMed  CAS  Google Scholar 

  116. Gall S, Addison WA, Hill GB: The use of moxalactam in the therapy of obstetric and gynecological infections. 20th Interscience Conference on Antimicrobial Agents Chemotherapy. New Orleans, La., Sept. 22–24, 1980, Abstract # 373

    Google Scholar 

  117. Kahan JS, Kahan FM, Goegelman R, et al.: Thienamycin, a new B-lactam antibiotic. I. Discovery and isolation. 16th Interscience Conference on Antimicrobial Agents and Chemother. Chicago, I11., 1976, Abstract # 227

    Google Scholar 

  118. Brown AG, Butterworth D, Cole M, et al.: Natural occurring B-lactamase inhibitors with antibacterial activity. J Antibiotics 29: 668–669, 1976.

    CAS  Google Scholar 

  119. Reading C, Cole M: Clavulanic acid a B-lactamase-inhibiting B-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 11: 852–857, 1977

    PubMed  CAS  Google Scholar 

  120. Kropp H, Sundelof JG, Kahan JS, et al.: MK0787 (N-Formimidoyl Thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother 17: 993–1000. 1980

    PubMed  CAS  Google Scholar 

  121. Kesado T, Hashizume T, Ashai Y: Antibacterial activities of a new stabilized thienamycin, N-formimidoyl Thienamycin, in comparison with other antibiotics. Antimicrob Agents Chemother 17: 912–917, 1980

    PubMed  CAS  Google Scholar 

  122. Tally FP, Jacobus NV, Gorbach SL: In vitro activity of N-Formimidoyl Thienamycin (MK0787). Antimicrob Agents Chemother 18: 642–644, 1980

    PubMed  CAS  Google Scholar 

  123. Neu HC, Labthavikul P: Comparative activity and ß-lactamase stability of N-formimidoyl thienamycin. 20th Interscience Conference Antimicrobial Agents Chemotherapy, New Orleans, La., Sept. 22–24, 1980, Abstract # 260

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, California, 94110, USA

    Richard L. Sweet M.D.

Authors
  1. Richard L. Sweet M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The New York Hospital — Cornell Medical Center, New York, N.Y., USA

    William J. Ledger

Rights and permissions

Reprints and permissions

Copyright information

© 1982 Martinus Nijhoff Publishers, The Hague

About this chapter

Cite this chapter

Sweet, R.L. (1982). Cephalosporins and Cephamycins. In: Ledger, W.J. (eds) Antibiotics in Obstetrics and Gynecology. Developments in Perinatal Medicine, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-7464-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-7464-7_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-009-7466-1

  • Online ISBN: 978-94-009-7464-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation